MedTrace Logo

Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia

NCT01919710 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2015-06-03

No results posted yet for this study

Summary

Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.

Conditions

  • Underdose (Unintentional)
  • Cancer
  • Tumor

Interventions

DRUG

rHSA/GCSF

for treatment of neutropenia

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Tianjin SinoBiotech Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun ZHU, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-06-30
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919710 on ClinicalTrials.gov